FIELD: medicine; pharmaceutics.
SUBSTANCE: present invention relates to a pharmaceutical composition in the form of a dry powder, suitable for administration by inhalation, containing: (i) particles of ensifentrine; (ii) large particles of lactose, having Dv50 from 40 mcm to 80 mcm; and (iii) fine lactose particles having Dv50 from 5 mcm to 10 mcm, where fine particles of lactose are present in amount of 0.1 wt.% to 6.0 wt.% relative to the total weight of the pharmaceutical composition in the form of a dry powder. Present invention also relates to medical use of the pharmaceutical composition in the form of a dry powder.
EFFECT: disclosed is a pharmaceutical composition containing ensifentrine.
15 cl, 6 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RAPAMYCIN-CONTAINING COMPOSITION ADMINISTERED BY INHALATION FOR TREATING AGE-RELATED DISEASES | 2015 |
|
RU2718583C2 |
| PHARMACEUTICAL COMPOSITIONS | 2004 |
|
RU2364400C2 |
| NEW CARRIER PARTICLES FOR DRY POWDER COMPOSITIONS FOR INHALATION | 2018 |
|
RU2745045C1 |
| RAPAMYCIN FOR TREATING LYMPHANGIOLEIOMYOMATOSIS | 2014 |
|
RU2707285C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING RPL554 IN HFA-134A FOR ADMINISTRATION BY INHALATION | 2019 |
|
RU2813959C2 |
| INHALATION PHARMACEUTICAL COMPOSITIONS | 2013 |
|
RU2697862C2 |
| NOVEL CARRIER PARTICLES FOR DRY POWDER INHALATION FORMULATIONS | 2020 |
|
RU2823554C1 |
| PHARMACEUTICAL DRUG FORMS CONTAINING LOW-DOSAGE ACTIVE COMPONENT FOR DRY POWDER INHALATORS | 2005 |
|
RU2371171C2 |
| INHALATION COMPOSITIONS CONTAINING MONTELEUKAST ACID AND PDE-4 INHIBITOR OR INHALATION CORTICOSTEROID | 2008 |
|
RU2470639C2 |
| COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | 2008 |
|
RU2484823C2 |
